ArticlePathology oncology research : POR2023

Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University.

Kata Ferenczi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.